RU2018113521A - Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b - Google Patents
Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b Download PDFInfo
- Publication number
- RU2018113521A RU2018113521A RU2018113521A RU2018113521A RU2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- influenza virus
- acid sequence
- residues
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims 27
- 229920001184 polypeptide Polymers 0.000 title claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 17
- 230000028993 immune response Effects 0.000 title claims 6
- 206010022000 influenza Diseases 0.000 title claims 2
- 241000700605 Viruses Species 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 101710154606 Hemagglutinin Proteins 0.000 claims 17
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 17
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 17
- 101710176177 Protein A56 Proteins 0.000 claims 17
- 239000000185 hemagglutinin Substances 0.000 claims 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 102000005348 Neuraminidase Human genes 0.000 claims 6
- 108010006232 Neuraminidase Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596014P | 2012-02-07 | 2012-02-07 | |
| US61/596,014 | 2012-02-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135703A Division RU2653756C2 (ru) | 2012-02-07 | 2013-02-06 | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018113521A true RU2018113521A (ru) | 2019-03-04 |
Family
ID=48947966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018113521A RU2018113521A (ru) | 2012-02-07 | 2013-02-06 | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b |
| RU2014135703A RU2653756C2 (ru) | 2012-02-07 | 2013-02-06 | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135703A RU2653756C2 (ru) | 2012-02-07 | 2013-02-06 | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9234008B2 (enExample) |
| EP (1) | EP2812348A4 (enExample) |
| JP (1) | JP6336915B2 (enExample) |
| KR (1) | KR20140127827A (enExample) |
| CN (1) | CN104136456A (enExample) |
| AU (2) | AU2013217166B2 (enExample) |
| BR (1) | BR112014018884A2 (enExample) |
| CA (1) | CA2863981A1 (enExample) |
| HK (1) | HK1203524A1 (enExample) |
| IN (1) | IN2014DN05805A (enExample) |
| MX (1) | MX2014009148A (enExample) |
| RU (2) | RU2018113521A (enExample) |
| SG (1) | SG11201404653UA (enExample) |
| WO (1) | WO2013119683A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011302360B2 (en) * | 2010-09-14 | 2015-01-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| EP3305806B1 (en) | 2012-02-13 | 2020-08-26 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| CA2868330A1 (en) | 2012-03-30 | 2013-10-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses |
| SG11201503989PA (en) | 2012-11-27 | 2015-06-29 | Univ Pittsburgh | Computationally optimized broadly reactive antigens for h1n1 influenza |
| CN107847579A (zh) * | 2014-12-19 | 2018-03-27 | 俄勒冈健康与科学大学 | 人和禽h5n1流感的计算优化的广泛反应性抗原的协同共同给药 |
| CA2987939A1 (en) | 2015-06-02 | 2016-12-08 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| CA2986701A1 (en) | 2015-06-09 | 2016-12-15 | Sanofi Pasteur, Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| US10485864B2 (en) | 2015-09-21 | 2019-11-26 | Oregon Health & Science University | Characterization of influenza vaccines |
| EP3464328A1 (en) * | 2016-06-02 | 2019-04-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| KR102731582B1 (ko) | 2016-06-03 | 2024-11-15 | 사노피 파스퇴르 인코포레이티드 | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 |
| US20210225457A1 (en) * | 2018-07-13 | 2021-07-22 | University Of Georgia Research Foundation | Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof |
| WO2020065349A2 (en) * | 2018-09-28 | 2020-04-02 | The Chancellor, Masters And Scholars Of The University Of Cambridge | Vaccines and methods |
| WO2024167855A1 (en) * | 2023-02-06 | 2024-08-15 | Emergent Product Development Gaithersburg Inc. | Influenza hemagglutinin constructs and compositions |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
| CN1311871C (zh) | 2000-03-02 | 2007-04-25 | 爱莫里大学 | Dna表达载体及其应用方法 |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| CA2816222A1 (en) * | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| CN101163714A (zh) | 2005-02-24 | 2008-04-16 | 马萨诸塞大学 | 流感病毒核酸、多肽及其用途 |
| WO2007072214A2 (en) | 2005-12-19 | 2007-06-28 | Novartis Vaccines And Diagnostics Srl | Methods of clustering gene and protein sequences |
| US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
| WO2007130327A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Influenza virus-like particle (vlp) compositions |
| WO2007134327A2 (en) * | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| US8980281B2 (en) | 2006-09-05 | 2015-03-17 | Academia Sinica | High-yield transgenic mammalian expression system for generating virus-like particles |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| EP2061887B1 (en) | 2006-10-04 | 2018-01-24 | The University Of Queensland | Vlp based influenza vaccine delivery system |
| WO2008145129A2 (en) * | 2007-05-31 | 2008-12-04 | Statens Serum Institut | Influenza vaccines |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| AU2008331673B2 (en) * | 2007-11-12 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
| KR101956910B1 (ko) * | 2008-01-21 | 2019-03-12 | 메디카고 인코포레이티드 | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ) |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| WO2010036970A2 (en) | 2008-09-25 | 2010-04-01 | Fraunhofer Usa, Inc. | Influenza vaccines, antigens, compositions, and methods |
| US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| JP5797636B2 (ja) | 2009-04-03 | 2015-10-21 | メリアル リミテッド | ニューカッスル病ウイルスをベクターとするトリワクチン |
| WO2011087839A1 (en) * | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
| US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| AU2011302360B2 (en) | 2010-09-14 | 2015-01-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
-
2013
- 2013-02-06 RU RU2018113521A patent/RU2018113521A/ru not_active Application Discontinuation
- 2013-02-06 EP EP13747212.2A patent/EP2812348A4/en not_active Withdrawn
- 2013-02-06 RU RU2014135703A patent/RU2653756C2/ru not_active IP Right Cessation
- 2013-02-06 BR BR112014018884A patent/BR112014018884A2/pt not_active IP Right Cessation
- 2013-02-06 SG SG11201404653UA patent/SG11201404653UA/en unknown
- 2013-02-06 KR KR1020147023368A patent/KR20140127827A/ko not_active Withdrawn
- 2013-02-06 CA CA2863981A patent/CA2863981A1/en not_active Abandoned
- 2013-02-06 MX MX2014009148A patent/MX2014009148A/es unknown
- 2013-02-06 WO PCT/US2013/024957 patent/WO2013119683A1/en not_active Ceased
- 2013-02-06 US US14/376,689 patent/US9234008B2/en active Active
- 2013-02-06 AU AU2013217166A patent/AU2013217166B2/en not_active Ceased
- 2013-02-06 IN IN5805DEN2014 patent/IN2014DN05805A/en unknown
- 2013-02-06 HK HK15104019.2A patent/HK1203524A1/xx unknown
- 2013-02-06 CN CN201380008469.3A patent/CN104136456A/zh active Pending
- 2013-02-06 JP JP2014555853A patent/JP6336915B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-29 AU AU2017204454A patent/AU2017204454A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014DN05805A (enExample) | 2015-05-15 |
| SG11201404653UA (en) | 2014-09-26 |
| JP2015506705A (ja) | 2015-03-05 |
| KR20140127827A (ko) | 2014-11-04 |
| CN104136456A (zh) | 2014-11-05 |
| CA2863981A1 (en) | 2013-08-15 |
| JP6336915B2 (ja) | 2018-06-06 |
| MX2014009148A (es) | 2014-09-22 |
| HK1203524A1 (en) | 2015-10-30 |
| US20150044247A1 (en) | 2015-02-12 |
| EP2812348A4 (en) | 2015-12-30 |
| RU2014135703A (ru) | 2016-03-27 |
| US9234008B2 (en) | 2016-01-12 |
| WO2013119683A1 (en) | 2013-08-15 |
| BR112014018884A2 (pt) | 2017-07-04 |
| AU2017204454A1 (en) | 2017-07-20 |
| RU2653756C2 (ru) | 2018-05-14 |
| AU2013217166B2 (en) | 2017-04-06 |
| AU2013217166A1 (en) | 2014-08-28 |
| EP2812348A1 (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018113521A (ru) | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b | |
| RU2017141447A (ru) | Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 | |
| RU2014101401A (ru) | Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств | |
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015506705A5 (enExample) | ||
| US11485759B2 (en) | Polypeptides for use in self-assembling protein nanostructures | |
| US10098946B2 (en) | Computationally optimized broadly reactive antigens for influenza | |
| RU2015124805A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 | |
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2016505538A5 (enExample) | ||
| US9896484B2 (en) | Influenza virus recombinant proteins | |
| CN114891074A (zh) | 一种季节性甲型流感通用病毒样颗粒及其制备方法与应用 | |
| Li et al. | A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection | |
| CN101899461A (zh) | 一种编码甲型流感病毒NP蛋白和M2e多肽的融合基因 | |
| Zhao et al. | Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses | |
| Krammer et al. | Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis | |
| CN115850395A (zh) | 一种流感病毒通用型纳米颗粒疫苗及其制备方法 | |
| JP2011088864A (ja) | インフルエンザウイルスに対するベクターワクチン | |
| Wu et al. | Hemagglutinin-encoded mRNA vaccine confers efficient protection against H3N8 avian influenza virus in Mice | |
| Kang et al. | Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate | |
| CN117045781A (zh) | 一种基于分子佐剂的广谱型h9亚型禽流感ha亚单位黏膜疫苗及其制备方法和应用 | |
| WO2024199469A1 (zh) | 具有稳定融合前构象的呼吸道合胞病毒f蛋白 | |
| CN112707954A (zh) | 一种禽流感通用表位疫苗 | |
| CN109821014A (zh) | 一种多抗原仿生流感疫苗及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160208 |